Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Itolizumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Equillium
Deal Size : Not Applicable
Deal Type : Not Applicable
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
Details : Itolizumab is a first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. Patients enrolled in EQUINOX trial will be randomized 1:1 to receive either itolizumab or placebo in addition to best supportive care for the treatment for...
Brand Name : EQ001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 29, 2020
Lead Product(s) : Itolizumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Equillium
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
